Edgewise Therapeutics Inc
NASDAQ:EWTX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.42
30.03
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Edgewise Therapeutics Inc
Revenue
Edgewise Therapeutics Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Edgewise Therapeutics Inc
NASDAQ:EWTX
|
Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$92.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$48B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$62.8B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$64.2B
|
CAGR 3-Years
3%
|
CAGR 5-Years
13%
|
CAGR 10-Years
5%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$59.4B
|
CAGR 3-Years
27%
|
CAGR 5-Years
21%
|
CAGR 10-Years
12%
|
|
Edgewise Therapeutics Inc
Glance View
Edgewise Therapeutics Inc. is a biopharmaceutical company that has carved its niche by focusing intently on developing treatments for rare muscle disorders. Founded with the vision of addressing the unmet needs within the realm of muscular dystrophies and other rare myopathies, Edgewise aims to combat these challenges through precision medicine. Its unique approach lies in leveraging its proprietary drug discovery platform to identify and develop small molecule therapies that target the underlying causes of these muscle disorders. By honing in on the mechanistic roots of muscle dysfunction, Edgewise aspires to improve the quality of life for patients who often have limited treatment options available. The company generates revenue primarily through the successful development and potential commercialization of its therapies. As with many biopharmaceutical entities, the cornerstone of Edgewise's financial strategy is to push its drug candidates through the clinical trial phases efficiently, demonstrating safety and efficacy to obtain regulatory approval. Partnerships, collaborations, and licensing agreements often play a critical role in supplementing its revenue stream, enabling Edgewise to leverage additional resources and expertise. By addressing the therapeutic gaps in rare muscle disorders with promising candidates that have the potential to be first-in-class or best-in-class treatments, Edgewise Therapeutics strategically positions itself to create significant value for its patients and stakeholders alike.
See Also
What is Edgewise Therapeutics Inc's Revenue?
Revenue
0
USD
Based on the financial report for Dec 31, 2024, Edgewise Therapeutics Inc's Revenue amounts to 0 USD.